Title : Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130).

Pub. Date : 2019 Dec 27

PMID : 31612909






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the PD-L1-positive subgroup, median PFS was 10.8 months (atezo + nab-P) versus 3.8 months (plac + nab-P; HR, 0.04; 95% CI, <0.01-0.35). nab CD274 molecule Homo sapiens